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Abstract
Background: Pharmacotherapy may represent a potential means to limit the expansion rate of abdominal aortic aneurysms
(AAAs). Studies evaluating the efficacy of different pharmacological agents to slow down human AAA-expansion rates have
been performed, but they have never been systematically reviewed or summarized.
Methods and Findings: Two independent reviewers identified studies and selected randomized trials and prospective
cohort studies comparing the growth rate of AAA in patients with pharmacotherapy vs. no pharmacotherapy. We extracted
information on study interventions, baseline characteristics, methodological quality, and AAA growth rate differences (in
mm/year). Fourteen prospective studies met eligibility criteria. Five cohort studies raised the possibility of benefit of beta-
blockers [pooled growth rate difference: 20.62 mm/year, (95%CI, 21.00 to 20.24)], but this was not confirmed in three
beta-blocker RCTs [pooled RCT growth rate difference: 20.05 mm/year (20.16 to 0.05)]. Statins have been evaluated in two
cohort studies that yield a pooled growth rate difference of 22.97 (25.83 to 20.11). Doxycycline and roxithromycin have
been evaluated in two RCTs that suggest possible benefit [pooled RCT growth rate difference: 21.32 mm/year (22.89 to
0.25)]. Studies assessing NSAIDs, diuretics, calcium channel blockers and ACE inhibitors, meanwhile, did not find statistically
significant differences.
Conclusions: Beta-blockers do not appear to significantly reduce the growth rate of AAAs. Statins and other anti-
inflammatory agents appear to hold promise for decreasing the expansion rate of AAA, but need further evaluation before
definitive recommendations can be made.
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Introduction
Current management recommendations for patients with small
abdominal aortic aneurysms (AAA) propose interval measurements
of aneurysm size until elective surgical repair is indicated based on
rapid expansion or size criteria ($5.5 cm) [1–3]. However, AAA
management based on such a ‘‘watchful-waiting’’ approach might
not be sufficient [4]. A more proactive strategy would be to identify
AAAs by screening and then to intervene therapeutically to slow
down AAA expansion with preventive measures [5].
A number of pharmacotherapies have potential to limit the
expansion rate of small AAAs. According to previous studies, the
mean growth rate of a small AAA is 0.3–0.5 cm/year [6]. Based
on this, experts propose that a reasonable therapeutic goal is to
identify therapies that reduce the expansion rate from 0.5 to
0.25 cm/year (50% effectiveness) so that the typical time for a
3 cm AAA to exceed the 5.5 cm threshold for surgical consider-
ation would be over 10 years.
According to the different AAA pathogenesis theories, a
combination of biomechanical wall stress, proteolytic degradation
of aortic wall connective tissue, and inflammatory/immune
response may be contributing to AAA expansion over time [7].
Correspondingly, anti-inflammatory drugs (e.g., doxycycline,
roxithromycine, and statins) and antihypertensive agents (e.g.,
ACE inhibitors, beta-blockers, diuretics, calcium antagonist) have
been proposed and formally tested as pharmacological agents that
may limit the expansion rate of small AAAs. Some of these agents
have demonstrated an effective suppression of induced aneurysm
formation in mouse models [8211]. Studies evaluating the efficacy
of these agents to slow down human AAA-expansion rates have
also been performed [12], but they have not to date been
summarized nor characterized.
Recognizing this, we performed a systematic review and meta-
analysis of prospective human studies (clinical trials or cohort
studies) that evaluated the efficacy or effectiveness of pharmaco-
therapies for reducing the expansion rate of AAA in patients with
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abdominal aortic diameter of 3.0 cm or greater. In conducting our
review, we set out to systematically identify the full spectrum of
pharmacological therapies that have been formally studied for the
indication of reducing AAA expansion.
Methods
Search strategy
Studies were identified by searching Medline (1966 through
October, 2006), EMBASE (1980 through October, 2006) and the
Cochrane Controlled Clinical Trials Register (1996 through
October 2006). Registered clinical trials were also searched on
the www.ClinicalTrials.gov website. We limited our research to
randomized controlled trials and cohort studies with a concur-
rent control group. We did not limit our research to any specific
pharmacotherapies, nor to any limited set of languages.
References of review articles and congress abstracts were also
searched, and a verification Medline and EMBASE search was
again performed in July 2007 to ensure that there we did not
miss any newly published studies. We derived 3 comprehensive
search themes that were then combined using the Boolean
operator ‘‘and’’. We created the first theme for AAAs by using an
exploded subject heading(s) and textword terms for abdominal
aortic aneurysm. The second theme for our interventions of
interest was created by using the Boolean search term ‘‘or’’ to
search for broad pharmacotherapy terms appearing as exploded
subject heading(s) and textword terms. We then created the third
theme for study designs of interest. Cohort studies were searched
by using the terms ‘‘risk’’, ‘‘prognosis’’, ‘‘cohort analysis’’ and
‘‘follow up study’’ and we then used the Boolean term ‘‘or’’ to
combine combined this with a published search filter for
identifying clinical trials [13]. More information on the research
strategy (i.e., subject heading(s) and textword terms) is available
on request.
Selection criteria
Two authors (IG, DP) independently reviewed each potential
study for eligibility on the basis of a predefined set of eligibility
criteria. AAA was defined as an aneurysm occurring below the
renal arteries and with a (anteroposterior or lateral) diameter of
3 cm or more. We excluded studies that did not report original
data, those assessing patients with AAAs previously treated by
surgery, those concerning aneurysms of other arteries, those
concerning infectious (e.g. mycotic) AAA and those with Marfan
syndrome. Pharmacotherapy interventions were defined as those
involving the prescription of a drug. Other interventions such as
behavioural interventions (e.g. smoking cessation) were not
eligible. The follow-up had to be at least 6 months and the AAA
size had to be assessed on at least two occasions for studies to be
included. The main outcome measure was the mean growth rate
difference in AAA diameter in mm/year between pharmaco-
therapy and control groups and expressed with standard
deviations (SD) or related measures of dispersion. To express
the size of the treatment effect in each trial, we used the
difference in means (MD) and the standard error of the
mean difference (SEMD), which is based on the standard
deviation and the number of participants for the intervention
group and the control group, respectively [14]. Therefore, we
included studies that either specifically reported SEMD, SD, or
other measures of dispersion (i.e. 95% confidence intervals, or
25–75% interquartile ranges) from which SD could be
calculated. We also included studies that did not report these
estimates but that provided raw data from which SD could be
calculated.
Data extraction and quality assessment
Two individuals (IG, DP) independently extracted data from all
primary studies fulfilling eligibility criteria. Abstracted information
included the study design (RCT or cohort study), the character-
istics of the specific pharmacotherapy assessed in each study
(including dosage and duration), the participants and study
characteristics (including gender, mean age, ethnicity and
proportion of smokers), as well as the type of device used to
measure the AAA diameter, the number of measurements
performed and the proportion of patients experiencing rupture
and/or undergoing surgical intervention during follow-up. We
also abstracted data on other study factors that can contribute to
heterogeneity in the results of efficacy of pharmacotherapy to
reduce the growth rate of AAA (i.e., baseline AAA diameter,
gender, age, ethnicity, smoking status, positive family history of
AAA, coronary heart disease). Any discrepancies in extracted data
were resolved by a third individual (WG).
The same two reviewers independently assessed the methodolog-
ical quality of identified studies. The quality of included clinical trials
was evaluated by using the quality assessment scale developed by
Jadad and colleagues [15]. In addition to Jadad’s scale, we also
considered the type of allocation concealment. For cohort studies,
meanwhile, we recorded the following quality indicators: the
approach to participant recruitment (consecutive vs. other approach-
es); the length of follow-up; and the consideration of confounding
factors. Finally, for both designs (RCT and cohort) we considered
whether studies had been stopped early for benefit and if there was an
a priori specification of sample size/power estimation.
Statistical analysis
Studies were classified according to the type of agent used (e.g.,
beta-blockers) and to the study design (i.e., clinical trial vs. cohort).
For pooling the results, we used the meta command in STATA.
The meta command uses inverse-variance weighting to derive
fixed-effects summary estimates of the treatment effect and the
DerSimonian and Laird method for random estimate. To limit the
sources of heterogeneity, we only estimated pooled growth rate
differences for groups of studies that share the same type of agent
and study design (e.g., RCTs evaluating beta-blockers). The
presence of heterogeneity across trials was evaluated using a chi-
square test for homogeneity [16] and random-effects and fixed-
effects were used accordingly to determine pooled estimates of the
growth rate difference across studies [17]. We also tested for
potential publication bias using both a Begg’s test for funnel plot
asymmetry and an Egger’s test [18,19]. These analyses testing for
publication bias were never significant across each of the meta-
analyses that we performed (detailed findings are thus not
reported). We conducted the statistical analyses using STATA
9.2 software (StataCorp, College Station, Texas).
Results
A total of 999 articles were identified by our initial search
strategy (figure 1). After an initial screening step based on abstracts
and article titles, 48 citations were judged to warrant further
review (inter-observer kappa= 0.85). Among these, 35 citations
were excluded for the following reasons: 6 did not report original
data, 5 reported data already published, 2 concerned aneurysms
other than AAAs, 7 were neither RCTs nor cohort studies, 9 were
studies where the intervention of interest was not a drug, and 6
were studies where AAA expansion rate was not an outcome. We
therefore identified 13 studies [20232] for inclusion in our review
(inter-observer kappa= 0.91 for the second step of selecting articles
based on full text review). Among these selected studies, 4 studies
AAA Pharmacotherapy
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met inclusion criteria but did not provide SD or equivalent to
calculate the SEMD. We contacted the authors of these 4 studies
[20,21,27,32] and were successful in obtaining data needed to
calculate SEMD for 3 of them [21,27,32].
Seventeen additional articles were then identified through a
process of scanning reference lists and congress abstracts. Among
these, 2 met eligibility criteria [33,34] and were thus included in
our review. As a result of this literature review process (figure 1),
we identified a final total of 14 studies for inclusion [21234].
Among these, one study [23] reported the results of four different
pharmacological agents (table 1).
Study characteristics
From 1988 to 2006, five RCTs [21,22,28,29,33] and 9
prospective cohorts studies [23227,30232,34] have evaluated the
efficacy of pharmacotherapies to reduce the growth rate of AAA
(table 1). A total of 4804 participants were included in these studies
(1995 in intervention groups, and 2809 in control groups). Two
general categories of pharmacological agents have been explored
within these studies: antihypertensive agents and anti-inflammatory
agents. Antihypertensive agents evaluated include beta-blockers
[21227,33], diuretics [23], ACE inhibitors [23], Ca channel
blockers [23] and unspecific antihypertensive agents [34]. Anti-
inflammatory agents studied include antibiotics with anti-inflam-
matory properties (doxycycline and roxithromycin) [28,29], statins
[30,31] and nonsteroidal anti-inflammatory drugs (NSAIDs) [32].
Participant characteristics in included studies
Age was generally reported in the included studies (10/14) and
participants’ mean age was 69.0 years. Participants were mostly men
Figure 1. Flow chart
doi:10.1371/journal.pone.0001895.g001
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in the 10 studies that reported sex of the patients
[21,22,25,26,28233]. The proportion of smokers (current and past
smokers), an established AAA risk factor, was only available in half of
the studies and varied from 17% to 72% [21,22,28232]. The preval-
ence of diabetes and hypertension were only available in four studies
[22,28,31,32]. Although recognized as AAA risk factors, neither
black race/ethnicity nor family history of AAA were reported in the
included studies. Finally, among the studies reporting the proportion
of participants with coronary heart disease (3/14), more than half of
participants had histories of coronary heart disease [22,30,31].
Annual growth rates
The mean AAA growth rates ranged across studies from
20.52 mm/year to 3.0 mm/year in the intervention groups and
from 0.1 mm/year to 4.4 mm/year in the control groups. By
medication category, the intervention and control AAA mean
growth rates were 1.75 mm/year and 2.47 mm/year for
beta blockers and controls, respectively; 1.53 mm/year and
2.87 mm/year for antibiotics and controls, respectively; and
0.74 mm/year and 3.8 mm/year for statins and controls,
respectively (table 2).
Table 1. Description of included studies
First Author,
Year
Study
design
Agent (number of
participants)
Type of control (number of
controls) Dosage (SD) Device
Mean Follow up
duration in months
Intevention Control
Beta blockers
Lindholt [21]
1999
RCT Propanolol (30) Placebo (24) 40 mg/bid US 24 24
PATI [22] 2002 RCT Propanolol (276) Placebo (272) 20–240 mg/d US 30 30
Wilmink [33]
2000
RCT Propanolol (256) No propanolol (221) 40 mg/d US{ 34{ 33{
Wilmink [23]
2002
Cohort{ Beta blockers* (77) No Beta blockers (255) NR US 48 48
Lindholt [24]
2001
Cohort Beta blockers* (25) No Beta blockers (112) NR US 28 28
Gadowski [25]
1994
Cohort Propanolol (21), Atenolol
(10), Metoprolol (7)
No Beta blockers (83) Propanolol 92 mg/d
(38), Atenolol
68 mg/d (30),
Metoprolol 80 mg/d
(21)
US 43 43
Leach [26] 1988 Cohort Propanolol (6), Selective
beta blockers* (6)
No Beta blockers (15) Propanolol 20–80 mg/d US 27 38
Biancari [27]
2002
Cohort Beta blockers* (17) No Beta blockers (24) NR US 87 87
Other antihypertensive agents
Wilmink [23]
2002
Cohort{ Diuretics* (54) No Diuretics (278) NR US 48 48
Wilmink [23]
2002
Cohort{ ACE inhibitors* (24) No ACE inhibitors (308) NR US 48 48
Wilmink [23]
2002
Cohort{ Ca channel blockers* (48) No Ca channel blockers (284) NR US 48 48
Brady [34] 2004 Cohort Antihypertensive* (932) No Antihypertensive (765) NR US NR NR
Antibiotics
Mosorin [28]
2001
RCT Doxycycline (17) Placebo (15) 150 mg/d US 18 18
Vammen [29]
2001
RCT Roxithromycin (40) Placebo (44) 300 mg/d US 18 18
Anti-inflammatory agents
Schouten [30]
2006
Cohort Simvastatin (24), Atorvastatin
(19), Fluvastatin (11),
Pravastatin (5)
No Statins (91) NR US 34 38
Sukhija [31]
2006
Cohort Simvastatin (31), Atorvastatin
(44)
No Statins (55) 20–80 mg/d CT 23 24
Walton [32]
1999
Cohort NSAID* (15) No NSAID (63) NR US .12 .12
*Without precision
{Same cohort study
{Data provided directly by the authors
NR Not reported
doi:10.1371/journal.pone.0001895.t001
AAA Pharmacotherapy
PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1895
Evidence on Efficacy of Beta-blockers
Beta blockers were evaluated in 3 RCTs [21,22,33] and in 5
prospective cohort studies [23227] and therefore are the most
studied agent. One of the RCTs has only been published as an
abstract [33]. A total of 1079 participants were studied in the 3
clinical trials, among whom 562 received propanolol, while 517
were control patients who did not receive beta blocker.
The other 5 cohort studies included 658 participants, among
whom 169 participants were treated with beta-blockers. Propan-
olol was the most frequently studied agent. Its dosage ranged from
20 mg/day to 240 mg/day. For three cohorts studies, neither the
type of beta-blockers nor the dosage were specifically reported
[23,24,27]. In addition to propanolol, one cohort study also
evaluated the effect of atenolol and metoprolol with mean doses of
68 mg/day and 80 mg/day, respectively [25].
Each of the three RCTs evaluating the efficacy of beta-blockers
did not individually show a significant difference in growth rate
[growth rate difference: 0.28 mm/year, (CI, 20.65 to 1.21),
20.40 mm/year, (CI, 20.89 to 0.09) and 20.04 mm/year, (CI,
20.16 to 0.08)] (table 2). Pooling of these RCTs results did not
reveal a significant growth rate difference [pooled growth rate
difference from a fixed effects analysis: 20.05 mm/year, (CI,
20.44 to 0.54), heterogeneity p = 0.29] (figure 2, Panel A).
Among the five beta-blockers cohort studies, two [24,27]
showed a significant growth rate reduction (table 2) and pooled
results from the 5 studies combined showed a significant reduction
in growth rate [pooled growth rate difference from a fixed effects
analysis: 20.62 mm/year, (CI, 21.00 to 20.24), hetereogeneity
p = 0.11] (figure 2, Panel B).
Evidence on efficacy of other antihypertensive
agents
In addition to beta-blockers, a cohort study by Wilmink and
colleagues [23] evaluated the efficacy of three other different
antihypertensive agents including diuretics, ACE inhibitors and
Ca channel blockers. Brady et al. [34], meanwhile, published the
results of a cohort study comparing the efficacy of ‘any
antihypertensive agent’ without specifying the agents used. We
report on this latter study in the general category of ‘‘other
antihypertensive agents’’.
Among other antihypertensive agents, all but diuretics had
lower growth rates in the intervention groups relative to the
corresponding control groups, but none of the observed differences
were statistically significant (table 2). The growth rate differences
were 0.10 mm/year for diuretics (CI 20.71 to 0.91), 20.78 mm/
year for ACE inhibitors (CI 21.58 to 0.02), 20.30 mm/year for
calcium channel blockers (CI 20.97 to 0.37) and 20.11 mm/year
for any antihypertensive agent (CI 20.34 to 0.12) [23,34]. Pooling
of these results was not performed because of the clinical
heterogeneity of the agents studied.
Table 2. Annual growth rate and growth rate difference
First Author, Year Study design Growth rate (SD) in mm/year
Growth rate
difference (mm/year) 95% CI
Intervention Control
Beta blockers
Lindholt [21] 1999 RCT 3.12 (2.5){ 2.84 (2.4){ 0.28 20.65 1.21
PATI [22] 2002 RCT 2.2 (2.9) 2.6 (3.0) 20.40 20.89 0.09
Wilmink [33] 2000 RCT 0.06 (0.6) 0.1 (0.6) 20.04 20.16 0.08
Wilmink [23] 2002 Cohort* 0.8 (2.6) 0.7 (3.2) 0.10 20.62 0.82
Lindholt [24] 2001 Cohort 1.6 (1.2) 2.5 (2.1) 20.90{ 21.54 20.26
Gadowski [25] 1994 Cohort 3.0 (3.9) 4.4 (4.2) 21.40 22.93 0.13
Leach [26] 1988 Cohort 1.7 (2.7) 4.4 (5.0) 22.70 25.69 0.29
Biancari [27] 2002 Cohort 1.56 (1.8){ 2.27 (1.9){ 20.71{ 21.42 0.00
Other antihypertensive agents
Wilmink [23] 2002 (diuretic) Cohort* 0.8 (2.6) 0.7 (3.4) 0.10 20.71 0.91
Wilmink [23] 2002 (ACEI) Cohort* 0.02 (1.6) 0.8 (2.6) 20.78 21.58 0.02
Wilmink [23] 2002 (Calcium blockers) Cohort* 0.5 (2.1) 0.8 (2.5) 20.30 20.97 0.37
Brady [34] 2004 (antihypertensives) Cohort NR NR 20.11 20.34 0.12
Antibiotics
Mosorin [28] 2001 (doxycycline) RCT 1.5 (2.2) 3.0 (4.3) 21.50 23.93 0.93
Vammen [29] 2001 (roxithromycin) RCT 1.56 (3.6) 2.75 (4.3) 21.19 23.25 0.87
Anti-inflammatory agents
Schouten [30] 2006 (statins) Cohort 2.0 (1.9) 3.6 (2.9) 21.60{ 22.38 20.82
Sukhija [31] 2006 (statins) Cohort 20.52 (3.0) 4.0 (3.0) 24.52{ 26.10 22.94
Walton [32] 1999 (NSAIDS) Cohort 2.5 (2.2){ 3.8 (2.4){ 21.30{ 22.59 20.01
*Same cohort study
{Data provided directly by the authors
{p value,0.05
NR Not reported
doi:10.1371/journal.pone.0001895.t002
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Evidence on efficacy of anti-inflammatory agents
(antibiotics, statins, NSAIDs)
Growth rate differences were generally larger in the studies
evaluating anti-inflammatory agents than they were for anti-
hypertensive agents (table 2). Growth rate difference exceeded
21.0 mm/year in favour of participants receiving doxycycline or
roxithromycin and were even as large as 24.0 mm/year in one
cohort study assessing statins [31]. However, upon pooling of
results across studies, only statins studies reached a statistically
significant level. Among the antibiotics studied, neither individual
study results [growth rate difference: 21.50 mm/year, (CI, 23.93
to 0.93) and 21.19 mm/year, (CI, 23.25 to 0.87)] nor pooled
results showed a significant decrease of growth rate [pooled growth
rate difference from a fixed effects analysis: 21.32 mm/year, (CI,
22.89 to 0.25), heterogeneity p = 0.84] (figure 2, Panel C). In
contrast, the two cohort studies assessing statins each showed a
significant growth rate reduction with a corresponding pooled
growth rate difference in a random effects analysis of 22.97 mm/
year (95% CI, 25.83 to 20.11, heterogeneity p,0.001) (figure 2,
Panel D).
Only one study by Walton et al. [32] evaluated the efficacy of
NSAIDs as a therapy for reducing the AAA growth rate on the
basis of its suppression of cyclooxygenase 2 activity [35]. Walton et
al. reported a statistically significant median growth rate difference
of 21.8 mm/year, favouring the NSAID group. We succeeded in
obtaining the mean growth rate (and SD) instead of the median
growth rate from the authors, and found results still favouring the
NSAID group (21.30 mm/year, 95% CI 22.59 to 20.01).
Quality indicators for RCTs and Cohort Studies
Table 3 presents our formal assessment of the RCT quality
criteria that constitute the Jadad quality assessment score. Three of
the five RCTs [22,28,29] achieve scores of 4 or higher, and can
therefore be characterized as high quality studies by that metric.
Recognizing that the Jadad quality scale provides only a partial
desription of RCT quality, we assessed additional RCT quality
indicators and report these for each of the five RCTs idenfied in
our review (table 4). It should be noted that RCT assessing beta-
blockers by Wilmink and colleagues [33] is only published as an
abstract; its quality was determined through review of an
unpublished draft manuscript that the authors provided for our
review.
Table 5 presents corresponding quality criteria for the 9 cohort
studies that were included in our review. Of note, the most positive
beta-blocker study [24] is one that fulfils only a few of the key
quality criteria for cohort studies. Similarly, among the statin
cohort studies, the strongly positive study by Sukhija et al. [31] also
meets only a few of the measured quality criteria.
Discussion
Our systematic review reveals that a number of pharmacother-
apies have been studied as potential therapies for decreasing the
growth rate of AAA. In fact, by not limiting our research to a
specific agent, we identified thirteen different agents that have
been studied either in cohort studies or RCTs since 1988. These
agents are representative of the following four classes: beta-
Figure 2. Panel A–D. Forrest plot of growth rate difference in mm/year between intervention and control group
doi:10.1371/journal.pone.0001895.g002
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blockers (propanolol, atenolol, metoprolol), other hypertensive
agents (diuretics, ACE inhibitors, Ca channel blockers), antibiotics
with anti-inflammatory properties (doxycycline, roxithromycin)
and other anti-inflammatory agents (simvastatins, atorvastatin,
fluvastatin, pravastatin, NSAIDs). Although the majority (11/14)
of studies using these agents report a trend toward a decrease of
AAA expansion, only five of them are statistically significant
[23,26,29,30,31]. The pooling of observational cohort study results
suggests that beta-blockers and statins may significantly reduce the
growth rate of AAA.
Such a conclusion, however, is not supported by corresponding
RCTs that reveal far less encouraging results for beta-blockers.
The evidence on statins, meanwhile, is only from cohort studies.
Observational studies are useful for assessing the relationship
between exposure (e.g., pharmacotherapy) and disease (e.g., AAA),
but they are subject to a number of potential biases [36]. The
promising results for statins based on two observational studies are
certainly important for hypothesis generation, but RCTs are now
needed to confirm this hypothesis.
For years, biomechanical wall stress mechanisms, atheroscle-
rotic processes and high blood pressure have been proposed as
causes of AAA formation [37]. Accordingly, the efficacy of
antihypertensive agents and particularly beta-blockers has been
evaluated. Propanolol was one of the first agents considered, and
although it appeared to reduce the growth rate of AAA in both
animals and human, its effectiveness was limited by the fact that
more than half of the patients dropped out of studies assessing this
treatment because of side effects [38]. Our systematic review
shows that the AAA growth rate difference between patients
treated with beta-blockers vs. controls ranges across studies from
22.70 to 0.28 mm/year. However, because the encouragingly
positive pooled result from cohort studies were not confirmed in
RCTs, we are led to conclude that the balance of published
evidence suggests that beta-blockers do not significantly reduce the
growth rate of AAAs, and that the use of beta-blockers, and
propanolol in particular, can not be recommended for this
indication.
More recently, pathophysiological considerations have suggest-
ed that the progressive loss of aortic medial vascular smooth
muscle cells and matrix in AAAs might be attributable to an
inflammatory process due to the proteolytic depletion of medial
and adventitial elastin [39,40]. These processes involve an
elastolytic proteinase called elastolytic matrix metalloproteinase
(MMP). In keeping with this inflammatory hypothesis, it has also
been proposed that an infectious agent, Chlamydia pneumonia, might
be involved as an initiating or accelerating agent in the process
leading to aneurysm formation and expansion [41,42]. Accord-
ingly, the efficacy of anti-inflammatory agents, including antibi-
otics, has been evaluated in a number of studies assessing the
growth rate of AAAs. Antibiotics were the first anti-inflammatory
agents evaluated in randomized trials. Mosorin et al. [28],
assessing doxycycline, found that the overall aneurysm expansion
rate during 18-month follow up was higher in the placebo group
(3.0 mm) than in the doxycycline group (1.5 mm), but the
difference did not reach statistical significance [28]. They
attributed their lack of statistical significance to their small sample
size (n = 32). Using a macrolide (roxithromycin) in a larger RCT,
Vammen et al. found a significant difference between the
intervention group and the control group after one year, but not
after a second year of follow-up [29]. Because our analysis
considered only the difference measured at the end of follow-up
for all studies, our meta-analysis reports a non-sigificant finding for
this latter study.
Because elastolytic matrix metalloproteinase (MMP) has been
implicated in AAA formation and expansion, drugs inhibiting
MMP action have been proposed as an approach to reducing the
growth rate of AAAs [43]. Intriguingly, recent immunohistochem-
istry studies and animals studies have shown that statins possess
MMP inhibiting properties [44247]. In keeping with this
hypothesis, the two cohort studies of statins that we identified in
our review [30,31] suggest a notable growth rate difference. As
mentioned earlier, however, this evidence is from non-randomized
cohort studies of statins, at least one of which [31] had suboptimal
study quality according to our assessment of cohort study quality
markers (table 5).
The assessment of study quality revealed that most studies
reported on the key indicators of quality. The most frequently
missing quality indicators concerned observational cohort
studies and consisted of incomplete or lack of reporting on losses
to follow-up, no report of adverse events, no sample size
specification, and the suboptimal reporting of important baseline
characteristics (e.g., smoking status, hypertension). Furthermore,
although we carefully searched and reported on quality indicators
among the included cohort studies, it should be emphasized that
the most important quality indicator is actually the study design.
Therefore, the results in our analysis emerging from RCTs should
be considered of higher quality than results from observational
cohort studies.
Table 3. Jadad’s score and quality indicators for RCTs
RCTs First Author, Year
Study
design
Randomisation
process
described
Allocation
sequence
appropriately
described
Describe as
double
blinding
Control treatment
described as
indistinguishable
Attrition
described (loss
of F/U, exclusion
reasons)
Jadad
score (0–5)
Beta blockers
Lindholt [21] 1999 RCT No No Yes NO Yes 2
PATI [22] 2002 RCT Yes No Yes Yes Yes 4
Wilmink [33] 2000 RCT Yes{ Yes{ No{* No{ Yes{ 3
Antibiotics
Mosorin [28] 2001 RCT Yes Yes Yes Yes Yes 5
Vammen [29] 2001 RCT Yes Yes Yes Yes Yes 5
*Single blinded
{Data provided directly by the authors
doi:10.1371/journal.pone.0001895.t003
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Our study has limitations. First, although we believe that we
have identified all available studies through a comprehensive and
sensitive search strategy and by seeking unpublished data from
study authors, it is possible that we have missed some studies.
Second, we found some evidence for statistical heterogeneity
among statins studies (figure 2, panel D) and the presence of
heterogeneity can compromise the interpretation [48]. These two
statin studies used different classes of statins and one of the studies
did not report the dose. These are clinical differences that may
have contributed to the heterogeneity of results that we observed.
We therefore emphasize the need to consider the corresponding
pooled growth rate difference for statins with caution. A third
general limitation to our review is that we would globally
characterize the body of literature that we have summarized as
being non-definitive, and in need of further study before firm
treatment recommendations can be made. With perhaps the
exception of the RCT beta-blocker evidence suggesting lack of
benefit, the studies assessing other therapies (including the
promising category of anti-inflammatory agents) is predominantly
observational in nature, and not optimal from the standpoint of
study quality and/or sample sizes. This global limitation, inherent
to the body of literature that we summarized, points to a need for
more RCTs assessing pharmacotherapies (especially anti-inflam-
matory therapies) for AAA growth rate reduction before more
definitive recommendations can be made. Finally, it is worth
noting that although AAA expansion rate is associated with the
risk of AAA rupture [49,50], and that expansion rate is
currently used as an indication for intervention (e.g. AAA repair)
[51], it is only a surrogate marker of increased rupture rate. The
use of surrogate markers as endpoints presents some study
feasibility advantages [52], but improvement in a surrogate
endpoint does not itself confer a definitive proof of patient benefit
(i.e., a decrease in risk of AAA rupture) [53]. Although both
statistical and mechanistic elements suggested that AAA expansion
rate is a valid surrogate marker of AAA rupture, definitive
inference is only likely when using the true clinical endpoint (i.e.
AAA rupture).
While we wait for such trials to be performed, clinicians will
rightly pose the question of whether they should now begin
prescribing various pharmacotherapies to patients with AAA? To
the best of our knowledge, our study is the first to systematically
review and meta-analyze the literature assessing this clinical
question. Although our review findings lead us to suggest that
beta-blockers do not reduce AAA growth rate, the use of surrogate
markers and the small number of RCTs assessing the efficacy of
beta-blockers do not definitively exclude the possibility of benefit
from beta-blockers. Anti-inflammatory agents, and in particular
statins, meanwhile, appear promising based on observational
cohort studies. In the absence of more definitive RCT evidence,
we cannot recommend use of these agents for the sole indication of
reducing AAA expansion rate. If, however, clinicians are in the
common scenario of having a patient with a AAA and
concomitant coronary artery disease and/or hyperlipidemia, we
would recommend the use of statins as these will provide
established benefit for the patient’s vascular disease risk, and
potentially also benefit to the rate of AAA expansion.
Our review indicates that beta-blockers do not significantly
reduce the growth rate of AAAs. Other pharmacotherapies, and
particularly anti-inflammatory agents, hold promise for reducing
the expansion rate of AAAs greater than 3cm. The literature
summarized, however, constitutes a non-definitive body of
evidence with most of the studies identified being observational
cohort studies. There is now a need for randomized controlled
trials in this area, particularly for the promising anti-inflammatory
agents.
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